Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2021

View Archived Issues

Bionomics enters MoU with EmpathBio to explore combination of BNC-210 and EMP-01 for PTSD

MK-6482 show promising activity in ccRCC both as monotherapy and in combination with cabozantinib

Phase I/II results presented for GT-005 in geographic atrophy

BITT and BeiGene enter option and license agreement for TNFR2 antagonists

Ultimovacs begins phase I study of TET-based vaccine for prostate cancer

Immunotherapy targeting AT1R ameliorates experimental insulin resistance

Oneness submits IND in U.S. for phase II study of FB-704A in severe asthma

Positive topline data from investigator-sponsored phase II study of IMU-838 in PSC

Phase II study of KHK-4083 in atopic dermatitis meets primary endpoint

Flexion advances FX-201 into high-dose cohort of phase I study in patients with knee osteoarthritis

Phase II study of Thykamine in atopic dermatitis meets its primary endpoint

Hoth plans to expand development of HT-003 for inflammatory bowel diseases

Enrollment ongoing in phase I study of TNB-486 in relapsed or refractory B-NHL

Rucaparib demonstrates promising activity in BAP1-negative or BRCA1-negative mesothelioma

PRMT5 as promising therapeutic target for glioblastoma

Bettering bile: New organoid marks progress to liver repair beyond hepatocytes

Phase II trial of imaging agent [64Cu]SARTATE enrolls patients with known or suspected NETs

AAV-mediated gene therapy FLT-201 shows robust potency for treating Gaucher disease

Rocket begins phase I study of RP-L401 in infantile malignant osteopetrosis

Orinove initiates phase Ib trial of oral ORIN-1001 in IPF

Dopamine progenitor cell product MSK-DA01 ameliorates Parkinsonian deficits in animal model

CHI3L1 is a risk marker for delirium in older patients undergoing surgery

Zebrafish used to model perivascular glioblastoma multiforme invasion

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...